Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094090

Enrollment

Unknown

Registered

2024-12-17

Start date

2024-12-31

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer, drug resistance after standard treatment, high expression of cmyc.

Interventions

Teniposide group:Teniposide administration

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Extensive stage small cell lung cancer; 2.Progression after receiving at least one chemotherapy drug treatment in the past; 3.ECOG score 0-1; 4.C-Myc-driven; 5.Expected survival period >=3 months; 6.Age: 18-75 years old; 7.The informed consent form complies with the ICH-GCP principles.

Exclusion criteria

Exclusion criteria: 1.No measurable lesions; 2.Other severe and persistent diseases or organ system dysfunction; 3.Women planning pregnancy or men planning family planning; 4.Women who are pregnant or breastfeeding; 5.Those who cannot follow the research protocol provided by the investigator.

Design outcomes

Secondary

Measure	Time frame
Disease Control Rate;Progression Free Survial;Duration of Response;	—

Primary

Measure	Time frame
Objective Response Rate;	—

Countries

China

Contacts

Public ContactRen shengxiang

Shanghai Pulmonary Hospital

harry_ren@126.com+86 13816756732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026